- Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland
An important component of nonverbal communication is gesture performance, which is strongly impaired in 2/3 of patients with schizophrenia. Gesture deficits in schizophrenia are linked to poor social functioning and reduced quality of life. Therefore, interventions that can help alleviate these deficits in schizophrenia are crucial. Here, we describe an ongoing randomized, double-blind 3-arm, sham-controlled trial that combines two interventions to reduce gesture deficits in schizophrenia patients. The combined interventions are continuous theta burst stimulation (cTBS) and social cognitive remediation therapy (SCRT). We will randomize 72 patients with schizophrenia spectrum disorders in three different groups of 24 patients. The first group will receive real cTBS and real SCRT, the second group will receive sham cTBS and real SCRT, and finally the third group will receive sham SCRT. Here, the sham treatments are, as per definition, inactive interventions that mimic as closely as possible the real treatments (similar to placebo). In addition, 24 age- and gender-matched controls with no interventions will be added for comparison. Measures of nonverbal communication, social cognition, and multimodal brain imaging will be applied at baseline and after intervention. The main research aim of this project will be to test whether the combination of cTBS and SCRT improves gesture performance and social functioning in schizophrenia patients more than standalone cTBS, SCRT or sham psychotherapy. We hypothesize that the patient group receiving the combined interventions will be superior in improving gesture performance.
Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT04106427].
Introduction
Schizophrenia is characterized by negative (e.g., affective flattening, avolition, low social drive) and positive symptoms (e.g., hallucinations, agitation, delusions) (1–3), as well as, disorganized thinking (4), motor abnormalities (5–7), and impaired cognitive function (8, 9). Social cognition, which refers to psychological processes that allow for the decoding of the behaviors and intentions of others (10–12), is also impaired in schizophrenia (13). In fact, impaired nonverbal communication is a core characteristic of social cognition deficits in patients with schizophrenia. Impaired nonverbal communication in schizophrenia includes limited nonverbal social perception (14–16) and poor gesture performance (17–19). Most importantly, gesture deficits are directly associated with patients’ poor functional outcome (20). This association between gesturing and functioning is the main reason why we believe that establishing treatments, which alleviate gesture deficits are essential to improve patients’ overall functioning and quality of life (21). Such treatments can potentially facilitate societal participation. With the current trial, we want to determine whether combined brain stimulation and group therapy improve schizophrenia patients’ gesture skills and social functioning.
Gesture Deficits in Schizophrenia
Gestures are an integral feature of communication: they support language production and transmit information on their own (22). Gesture deficits are prevalent in approximately two-thirds of patients with schizophrenia (17, 18, 23). Accumulating evidence suggests that various domains of gesturing are impaired in schizophrenia, including use of gestures (17, 18, 24, 25) and gesture perception (26). In fact, individuals with schizophrenia often use incoherent and fewer gestures (17, 27, 28) and tend to interpret gestures negatively (29, 30).
Gesture deficits in patients are associated with core schizophrenia symptoms, e.g., negative symptoms (24, 27), frontal lobe dysfunction (17, 18), formal thought disorder (23, 31) and working memory impairments (15, 24). At a neural level, gesture processing involves the praxis network, which combines motor- and speech-related brain areas (32, 33). Neuroimaging demonstrated structural and functional alterations in the praxis network in schizophrenia patients with gesture deficits (34–38). Specifically, two areas of the praxis network are linked to gesture deficits in schizophrenia: the inferior parietal lobule (IPL) and the inferior frontal gyrus (IFG) (39, 40). The IPL has been related to motor functioning, as well as cognitive and visuospatial processing (41–43). The IFG has been associated with motor functioning and language production (44).
Interventions Improving Gesture and Social Skills
Brain Stimulation
Repetitive transcranial magnetic stimulation (rTMS) has the potential to (re-)train distinct neural pathways and therefore rehabilitate specific functions in multiple neuropsychiatric disorders (45). Recent studies demonstrated rTMS efficacy across different domains in patients with schizophrenia. For example, rTMS over the supplementary motor area (SMA) ameliorated motor abnormalities (46, 47) and rTMS over the inferior parietal lobe (IPL) improved gesture performance (48). Different rTMS protocols can have different effects on brain function, depending on their frequency and type of stimulation (49).
Theta burst stimulation (TBS) is an innovative rTMS protocol, which requires less time than standard rTMS. There are two types of TBS: intermittent theta burst stimulation (iTBS), which mainly has facilitatory effects and continuous theta burst stimulation (cTBS), which has inhibitory effects. A pilot study demonstrated that inhibitory cTBS over the right inferior parietal lobe (rIPL) improved gesture performance by comparing 3 rTMS protocols (including sham stimulation) in 20 patients (48). Due to interhemispheric rivalry, cTBS on the right IPL may induce a facilitatory effect on left IPL through transcallosal disinhibition (50). As such, inhibitory cTBS over the rIPL is a promising method to reduce gesture deficits in schizophrenia. We decided to use the same cTBS protocol for repetitive administration in a larger sample.
Social Cognitive Remediation Therapy
Social cognition is a main driver of recovery and functional outcomes (10, 51–53) and mediates the relationship between neurocognition and social functioning in schizophrenia (53). The MATRICS initiative (Measurement and Treatment Research to Improve Cognition in Schizophrenia) of the National Institute of Mental Health (NIMH) identified the most important cognitive domains in schizophrenia (10, 54). These consist of six neurocognitive domains: speed of processing (1), attention/vigilance (2), working memory (3), verbal learning (4), visual learning (5) and reasoning/problem solving (6) and five social-cognitive domains: emotion processing (1), social perception (2), theory of mind (3), social schemata/knowledge (4) and social attribution styles (5). Therapies focusing on both neurocognition and social cognition are suggested to be a promising approach to help patients with schizophrenia (55–57).
One of the few integrative cognitive remeditation therapies (CRT) covering all MATRICS domains is the Integrated Neurocognitive Therapy (INT) (58, 59). This CRT approach takes place in a group setting, including social interactive tasks and computerized neurocognitive exercises (using the Cogpack program). INT showed good feasibility with reduction of positive symptoms, negative symptoms and relapses, as well as, improvements in social cognition, neurocognition, and overall functioning in patients with schizophrenia (56, 60–62). The INT includes four modules, each addressing various cognitive domains: processing speed, attention, and perception of emotions (1); verbal and visual learning, memory, social perception, and theory of mind (2); reasoning, problem solving, and social schema (3); working memory and the ability to attribute appropriate meanings (4). INT focuses on the improvement of both social cognition and neurocognition, with more focus on the latter.
Social cognitive remediation therapy (SCRT) is an approach focusing mainly on social cognition in patients with schizophrenia (58, 63). As of today, two types of SCRTs are being developed: targeted and broad-based SCRTs. Targeted SCRTs address only the remediation of one specific social cognitive deficit (e.g., facial affect recognition) (64), whereas broad-based SCRTs address multiple social cognitive domains (65). Integrative broad-based SCRTs combine the improvement of social cognitive domains with other therapy techniques, such as Cognitive Behavioral Therapy (CBT) (66), cognitive remediation (67, 68) or social skills training (69–71). It is advisable to use an integrative approach involving both neurocognitive and social-cognitive domains, as these lead to greater generalization effects on functional outcome (53, 72, 73). In light of previous studies, we consider integrative broad-based SCRTs a promising treatment to reduce social cognitive impairments and enhance functioning in schizophrenia. Therefore, we decided to use this type of treatment approach for the current study.
Methods
Aims and Hypotheses
This study’s main goal is to determine the effects of combined cTBS over rIPL and SCRT on gesture performance and social functioning in patients with schizophrenia. In addition, we aim to investigate neurocognitive, social cognitive, motor, clinical and neural effects of both interventions as secondary outcome measures. As cTBS enhances neuroplasticity and improves use of neural resources (46, 74), we expect administration of cTBS to facilitate SCRT training effects. Additionally, we hypothesize that the expected improvement of gesture performance will have positive effects on functional outcome, as both have been reported to be linked in schizophrenia (20). At the neural level, we hypothesize that the brain activity of patients will converge to the brain activity of healthy controls after both interventions, especially within the praxis network (39, 40).
This randomized controlled trial (RCT) will include three patient groups (see Figure 1). First, group A will receive real cTBS and real SCRT. Second, group B will receive sham cTBS and real SCRT. Third, group C will receive no cTBS and sham SCRT. In this study, we will also include a fourth group consisting of healthy controls, who will be assessed twice without any intervention in between. We expect the combination of cTBS and SCRT to show positive effects on both primary and secondary outcomes in patients with schizophrenia spectrum disorders. As such, we expect group A to have superior performance over group B and C in gesture performance and functional outcome after intervention (A > B > C).
Figure 1. Study Setup. We will randomize 72 schizophrenia patients in three different groups (24 patients per group). Group A will receive real cTBS and real SCRT. Group B will receive sham cTBS and real SCRT. Group C will receive no cTBS and sham SCRT. Both sham treatments are inactive interventions that mimic as closely as possible the real treatments. Group A and B will receive 10 cTBS sessions during the first two weeks of intervention. Additionally, Group A–C will receive 16 SCRT sessions for eight weeks. Outcomes will be measured during four different time points: baseline, after cTBS (week 2), after SCRT (week 8) and follow-up (week 32). We will also include a fourth group consisting of 24 healthy controls, who will be assessed twice (baseline and week 8) without any intervention in between.
Setting and Enrollment
Study Design
This will be a three-arm, double-blind, randomized, sham-controlled trial of add-on brain stimulation and SCRT to improve nonverbal communication skills and overall functioning in schizophrenia spectrum disorders. This single-site trial will be conducted at the University Hospital of Psychiatry and Psychotherapy, Bern.
Study Population
Patients will be asked for participation at the outpatient departments of the University Hospital of Psychiatry and Psychotherapy, Bern and will be screened with the Structured Clinical Interview for DSM-5 (SCID). Healthy participants will be recruited by word-of-mouth and flyers in public places (e.g., grocery stores, pharmacies, gyms) in Bern. Participants will be eligible for study entry if they meet the criteria listed in Table 1.
Interventions
Implementation of Real/Sham Continuous Theta Burst Stimulation
Patients will receive ten cTBS sessions in total during the first 2 weeks of intervention. Each session (sham and real cTBS) will last 17 min consisting of two 44 s stimulations over rIPL separated by a 15-min break. For each stimulation of 44 s, we will apply 801 pulses at 50 Hz over the right IPL at an intensity of 100% of the resting motor threshold. Hence, the entire session will consist of 1,602 pulses. Sham cTBS will be delivered with a placebo-coil without any magnetic emission.
Implementation of Real/Sham Social Cognitive Remediation Therapy
Real/sham SCRT will be conducted bi-weekly for 8 weeks, totaling 16 sessions of 90 min. Each group will consist of six to eight patients led by a head-therapist (VC) and a co-therapist (FW). INT-expert (DM) will train both therapists and supervises the course of the sessions.
For this trial, we will tailor an SCRT based on the INT manual (58, 59). This SCRT will include the entire social cognitive part of the original INT (consisting of a minimum of 30 sessions) and two INT neurocognitive modules. As such, we will use psychoeducation and Cognitive Behavioral Therapy for Psychosis (CBTp) techniques. This intervention will have the main goal of improving gesture deficits in schizophrenia and will be separated in five blocks; each including neuro- and social cognitive MATRICS-domains (see Table 2). The first, third and fifth block will focus predominantly on using and interpreting nonverbal cues in social contexts. The second and fourth blocks will address memory and attention, both of which are essential for functioning in social interaction. Three sessions will be dedicated to each block, totaling 15 sessions overall. With each session, the content of the blocks will increase in complexity. A final 16th session will be added, in which the content delivered in all previous five blocks will be summarized.
Figure 2. Three fMRI gesture tasks—experimental setup. (A) Gesture planning/performance task with the modified Test of Upper Limb Apraxia (TULIA). Participants will be presented with 20 hand gestures in a random order (e.g., wave good-bye) and 10 control sentences with no gesture performance expected (e.g., “the airline flight is delayed”). Each trial will start with an instruction (3 s), followed by a triangle (planning phase: 3 s), then a 3–10 s interstimulus interval with a fixation cross (3–10 s), a circle (execution phase: 3 s), another 3–6 s interstimulus interval, and then a new gesture of the next trial is presented. (B) Gesture perception task with the modified Postural knowledge task (PKT). Each trial will start with a fixation cross (3–10 s) followed by a picture (max. 5 s) where the hand of the presented figure will be removed. Participants’ task is to choose the correct hand gesture provided below using button presses of a hand pad inside the scanner (1, 2, and 3) and respond while the picture is still displayed. In the example provided the correct gesture is number two. (C) Gesture interpretation task with point-light displays (PLD). Each trial will start with a fixation cross (3–10 s) followed by a PLD video, after which a question mark will be displayed (3 s). The video will include two PLD figures: one on the right side and the other on the left side of the screen. During the video, one PLD will perform a gesture while the other PLD will either follow or imitate these performed gestures. Participants’ task will be to indicate with the button press of a hand pad which of the two PLD figures (left or right) is imitating or following the gestures of the other when the question mark will be displayed. The gray connecting lines and the two gray circles (i.e., PLDs’ heads) are a visual aid and will not be present in the actual experiment.
Each block will start with an introductory session, followed by a training session (i.e., compensation and restitution sessions), and a transfer session (see Table 2). During the introductory sessions, the MATRICS domains will be presented with a great focus on their everyday use and individual self-reference. The introductory sessions include psychoeducation on the respective neurocognitive and social domains. During the training sessions, we will determine patients’ strongest coping strategies, establish solution-oriented awareness, and train cognitive domains with various exercises (e.g., computerized cognitive tasks or role play exercises). The transfer sessions will work on the principle “rehearsal learning” (75, 76), meaning patients repeatedly apply the newly learned strategies in their daily life to restore social cognitive functions. The treatment goal will be to develop more coping strategies and enhance social skills to increase overall functioning. The therapists will follow a script for quality assurance and treatment fidelity.
Sham SCRT will consist of psychoeducation on sleep hygiene, exercise, stress, and music, as well as leisure activities, and mindfulness-based exercises (e.g., raisin meditation or walking meditation in a nearby park in Bern). Patients receiving this group therapy will also benefit from an interactive environment. The main difference with the real SCRT will be that sham SCRT will not include any (social) cognitive training, nor active transfer of skills into daily life.
Primary and Secondary Outcomes
Behavioral and Clinical Assessments
The primary outcome of this study will be hand gesture performance, which will be assessed with the Test of Upper Limb Apraxia (TULIA) (77). TULIA includes 48 items in two domains: Imitation (following demonstration) and pantomime (after verbal command). The test has three semantic categories of gestures: communicative (intransitive), object-related (transitive), or meaningless. Item ratings range from 0 to 5. If the participants make content errors (e.g., perseverations, substitutions), they will get 0–2 points per item. If the participants make spatial or temporal errors, they will get 3–4 points. Perfect performance equals 5 points, which is the maximum score per item. The highest TULIA total score is 240. A cutoff score will be used to measure gesture deficits in schizophrenia with < 210 TULIA total score (17). Gesture performance will be recorded on video and later evaluated by an independent examiner who is blinded to the groups or timing of the assessment. We will assess gesture performance using TULIA at four different time points (see Table 3).
Secondary outcomes will include additional nonverbal communication, cognitive, clinical, and functional assessments, as well as self-reports. Nonverbal communication will be tested with the Profile of Nonverbal Sensitivity (PONS) (78) assessing nonverbal social perception, and the modified postural knowledge task (79, 80) measuring gesture perception. Together, TULIA, PKT, and PONS assess nonverbal communication, as they include the production, the recognition, and the interpretation of gestures. History of symptoms and medication in patients will be assessed with The Comprehensive Assessment of Symptoms and History (CASH) (81). Self-reports, clinical scales, motor scales, cognitive tests and functional assessments are listed in Table 4.
Outcomes will be measured during four different time points: baseline, after cTBS (week 2), after SCRT (week 8) and follow-up (week 32) (see Table 3). At baseline, week 8 and week 32, the primary and all secondary outcomes will be tested. At week 2, the primary and a few secondary outcomes (i.e., nonverbal communication and clinical assessments) will be measured. Additionally, at baseline and week 8, neuroimaging data will be acquired to test the neural effects of the treatments.
Magnetic Resonance Imaging Measurements
Neuroimaging will include structural T1, arterial spin labeling (ASL), diffusion tensor imaging (DTI), blood oxygenation level dependent (BOLD) resting state and fMRI tasks. MRI acquisition will be performed at a 3T SIEMENS MAGNETOM Prisma at the Swiss Institute for Translational and Entrepreneurial Medicine (SITEM), Bern, Switzerland. We will use a 20-channel radio-frequency head coil (Siemens, Germany) for all acquisitions.
Functional Magnetic Resonance Imaging and Tasks
We will administer three different fMRI tasks to assess gesture planning/execution, perception, and interpretation (see Figure 2). First, gesture planning and performance will be assessed with an adapted version of the gesture task created by Stegmayer et al. (39) and Kroliczak and Frey (82). In an event related design, participants will be presented with 30 gestures in a random order: 10 meaningless (e.g., “raise your thumb and your index finger”), 10 meaningful gestures (e.g., “wave good-bye”) and 10 control sentences with no gesture performance expected (e.g., “the weather is bad”). Second, we will use the Postural Knowledge Task (PKT) (15, 26, 80) to assess participants’ gesture perception. Participants will be presented with pictures of people performing gestures (20 trials), while the hands executing those gestures are missing. Participants will be asked to choose the correct hand gesture from three choices provided. In the control condition (20 pictures), participants will be asked to indicate if the person performing the gesture is either male or female. Third, we will use the point-light-display (PLD) method to assess dynamic gesture perception. Here, human biological movements will be depicted by 12 point-light dots on the main joints of a human actor in the absence of any other visual characteristics (83–85). For our task, 40 videos of one PLD agent will be shown to perform different communicative gestures while the other PLD agent imitated/followed these performed gestures (26, 86). Participants’ task will be to identify which PLD was imitating/following the other.
Allocation and Randomization
Interventions will start in blocks as soon as 6–8 participants can be randomized to three groups: Group A, group B or group C (see Figure 1). Patients will not know which treatment they receive; they will be allocated to one of three treatment arms in a blinded manner.
Statistical Considerations and Plan
Assuming a medium effect size (f = 0.15) in a repeated measures ANOVA with moderate-high correlation between time points (0.75), a power of 0.95 and an alpha = 0.05, we will need 72 patients (24 per group). In addition, a control group of 24 healthy subjects will be required. All four groups will be compared pre-to-post with an interval of 8 weeks (see Figure 1). The main effects of the combined interventions on the primary and secondary outcomes will be calculated in a repeated measures design including 3 main time points (Baseline, week 2, and week 8) and three patient groups (A, B, and C). With the latest SPSS and R versions, we also will run additional (partial) correlations, linear regressions, MANCOVAS using covariates (e.g., age, education, and medication).
Trial Status
Study recruitment started on the 17th December 2019. The first group started with both interventions on the 24th February 2020. The study was impacted by the federal measures against the COVID-19 pandemic. As of June 2022, we recruited 65 patients and 36 healthy controls. We completed baseline assessments with 62 patients and 33 healthy controls. We finished week-8 assessments with 36 patients and 32 controls.
Discussion
Relevance of the Current Study
With this study, we will run one of the few prospective, sham-controlled RCTs addressing both gesture deficits and poor functioning in schizophrenia. Ameliorating functional outcome as a means of reintegrating patients into society has become one of the most central goals of psychiatric rehabilitation (87–89). Despite advances in antipsychotic medications and psychotherapies, functional recovery rates of schizophrenia patients have not increased substantially over the last 30 years (90, 91). Schizophrenia is not only a major burden for patients, but also a great economic strain for society, as patients with schizophrenia make heavy use of inpatient services and require financial support. It is urgent to develop psychiatric treatments that help patients to maintain interpersonal relationships and facilitate independent living. As gesture deficits in schizophrenia are highly correlated to overall functioning in daily life (20) and effective therapies reducing nonverbal communication deficits are lacking, it is clear that we need to establish interventions that tackle both (46, 92).
Advantages
The design of this RCT encompasses numerous advantages. The main strength of our study is the combination of two interventions; coupling brain stimulation with group therapy may exert cumulative therapeutic effects in gesturing and functioning in schizophrenia (20). Additionally, cTBS enhances neuroplasticity in schizophrenia patients (46, 74) and thus, may facilitate SCRT training effects. Thanks to the two comparators (sham cTBS and sham SCRT) we can evaluate the therapeutic effects of both interventions on behavioral, clinical, and neural levels. Also, we may find insights to predictors of treatment outcome. Further, the RCT design allows elimination of selection bias in treatment assignment and enables blinding from assessors and participants. Moreover, by collecting detailed demographic information over time, we will be able to correct for age, gender, education and antipsychotic medication dosage. Longitudinal data allows exploration of change in our patients, and thus, gives insight on the longevity of treatment effects. For example, our design may shed light on factors that are essential for the transfer of coping strategies. Most importantly, we are running one of the very few RCT on SCRT to involve acquisition of neuroimaging data before and after intervention. We can directly compare neural alterations to potential behavioral changes after the interventions. If this study proves to be successful it has the potential to be beneficial for other psychiatric disorders, which exhibit similar socio-cognitive dysfunctions such as depression (93, 94).
Limitations
This RCT entails a few limitations. First, we cannot eradicate the influence of medication; most patients suffering from schizophrenia are on antipsychotic treatment and other medication (e.g., blood pressure suppressants, antidepressants). However, for antipsychotic medication, we will control for Olanzapine equivalents in our statistical analyses. Second, we cannot eliminate gains linked to repeated test exposure as a result of retaking the same test under comparable conditions (i.e., retest effects). We counter these effects by randomizing the order of our test items for most of our assessments. Additionally, the time between most of our assessments makes training effects quite unlikely (i.e., 8 weeks, 32 weeks). Third, some of the data we collect are self-reports. Due to the subjective nature of self-reports, their psychometric aspects (e.g., reliability and validity) can be questionable or subject to biases (e.g., response bias). However, self-reports are necessary. For example, it is essential to compare patients’ subjective symptoms before and after intervention to find out if we are helping them. Fourth, another concern is the generalizability of the trial results. Participation in our study is only appropriate for a subgroup of schizophrenia patients, as it consists of 30 meetings in 3 months. As such, we can only include stable outpatients with good time management, commitment and tolerance to additional stress. This might cause the data collection to become arduous and dropout rates to be high.
Conclusion
In summary, this study explores the combination of cTBS and SCRT to improve gesture skills and social functioning in schizophrenia. This research project is of great importance as treatment options alleviating nonverbal communication deficits are clearly lacking. If this study proves to be successful, it has the potential to change the course of current treatment methods and greatly improve social functioning, as well as the quality of life of patients with schizophrenia.
Ethics Statement
The studies involving human participants were reviewed and approved by the Kantonale Ethikkommission Bern (KEK). The patients/participants provided their written informed consent to participate in this study.
Author Contributions
VC contributed to recruits participants, organizes the study procedures, conducts assessments, carries out both interventions, and drafted the manuscript. AP supervised the study procedures. DM trained the head therapist and co-therapists in SCRT and supervised the SCRT sessions. SW designed the study, obtained funding and ethics approval, wrote the study protocol, and registered the study at the clinical trials. All authors discussed and critically revised the manuscript.
Funding
This study was funded by the Swiss National Science Foundation (grant #184717 to SW).
Conflict of Interest
SW was received honoraria from Mepha, Neurolite, Janssen, Lundbeck, Otsuka, and Sunovion.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We thank Florian Weiss (FW) and Florence Ibrahim for being our SCRT co-therapists. We thank Karl Verfaillie for providing us with the PLD videos.
Abbreviations
ASL, arterial spin labeling; BOLD, blood-oxygen-level-dependent imaging; CBTp, Cognitive Behavioral Therapy for Psychosis; cTBS: continuous theta burst stimulation; DTI, diffusion tensor imaging; fMRI, functional magnetic resonance imaging; IFG, inferior frontal gyrus, iTBS, intermittent theta burst stimulation; IPL, inferior parietal lobule; MATRICS, Measurement and Treatment Research to Improve Cognition in Schizophrenia; MRI, magnetic resonance imaging; PKT, postural knowledge test; PLD, point-light-display; PONS, profile of nonverbal sensitivity; RCT, randomized controlled trial; rIPL, right inferior parietal lobule; rTMS, repetitive transcranial magnetic stimulation; SCRT, social cognitive remediation therapy; SMA, supplementary motor area; TULIA, Test of upper limb apraxia.
References
1. Dollfus S, Lyne J. Negative symptoms: history of the concept and their position in diagnosis of schizophrenia. Schizophr Res. (2017) 186:3–7. doi: 10.1016/j.schres.2016.06.024
2. Carra G, Crocamo C, Angermeyer M, Brugha T, Toumi M, Bebbington P. Positive and negative symptoms in schizophrenia: a longitudinal analysis using latent variable structural equation modelling. Schizophr Res. (2019) 204:58–64. doi: 10.1016/j.schres.2018.08.018
3. Mccutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. JAMA Psychiatry. (2020) 77:201–10. doi: 10.1001/jamapsychiatry.2019.3360
4. De Sousa P, Sellwood W, Griffiths M, Bentall RP. Disorganisation, thought disorder and socio-cognitive functioning in schizophrenia spectrum disorders. Br J Psychiatry. (2019) 214:103–12. doi: 10.1192/bjp.2018.160
5. Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. (2012) 66:77–92. doi: 10.1159/000339456
6. Walther S, Mittal VA. Motor system pathology in psychosis. Curr Psychiatry Rep. (2017) 19:97. doi: 10.1007/s11920-017-0856-9
7. Nadesalingam N, Chapellier V, Lefebvre S, Pavlidou A, Stegmayer K, Alexaki D, et al. Motor abnormalities are associated with poor social and functional outcomes in schizophrenia. Compr Psychiatry. (2022) 115:152307. doi: 10.1016/j.comppsych.2022.152307
8. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. (2009) 110:1–23. doi: 10.1016/j.schres.2009.03.005
9. Guo JY, Ragland JD, Carter CS. Memory and cognition in schizophrenia. Mol Psychiatry. (2019) 24:633–42. doi: 10.1038/s41380-018-0231-1
10. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. (2004) 72:29–39. doi: 10.1016/j.schres.2004.09.007
11. Frith CD, Frith U. Social cognition in humans. Curr Biol. (2007) 17:R724–32. doi: 10.1016/j.cub.2007.05.068
12. Adolphs R. The social brain: neural basis of social knowledge. Annu Rev Psychol. (2009) 60:693–716. doi: 10.1146/annurev.psych.60.110707.163514
13. Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci. (2015) 16:620–31. doi: 10.1038/nrn4005
14. Toomey R, Schuldberg D, Corrigan P, Green MF. Nonverbal social perception and symptomatology in schizophrenia. Schizophr Res. (2002) 53:83–91. doi: 10.1016/S0920-9964(01)00177-3
15. Walther S, Stegmayer K, Sulzbacher J, Vanbellingen T, Muri R, Strik W, et al. Nonverbal social communication and gesture control in schizophrenia. Schizophr Bull. (2015) 41:338–45. doi: 10.1093/schbul/sbu222
16. Chapellier V, Pavlidou A, Maderthaner L, Von Känel S, Walther S. The impact of poor nonverbal social perception on functional capacity in schizophrenia. Front Psychol. (2022) 13:804093. doi: 10.3389/fpsyg.2022.804093
17. Walther S, Vanbellingen T, Muri R, Strik W, Bohlhalter S. Impaired gesture performance in schizophrenia: particular vulnerability of meaningless pantomimes. Neuropsychologia. (2013) 51:2674–8. doi: 10.1016/j.neuropsychologia.2013.08.017
18. Walther S, Vanbellingen T, Muri R, Strik W, Bohlhalter S. Impaired pantomime in schizophrenia: association with frontal lobe function. Cortex. (2013) 49:520–7. doi: 10.1016/j.cortex.2011.12.008
19. Walther S, Mittal VA, Stegmayer K, Bohlhalter S. Gesture deficits and apraxia in schizophrenia. Cortex. (2020) 133:65–75. doi: 10.1016/j.cortex.2020.09.017
20. Walther S, Eisenhardt S, Bohlhalter S, Vanbellingen T, Muri R, Strik W, et al. Gesture performance in schizophrenia predicts functional outcome after 6 months. Schizophr Bull. (2016) 42:1326–33. doi: 10.1093/schbul/sbw124
21. Walther S, Mittal VA. Why we should take a closer look at gestures. Schizophr Bull. (2016) 42:259–61. doi: 10.1093/schbul/sbv229
22. Goldin-Meadow S, Alibali MW. Gesture’s role in speaking, learning, and creating language. Annu Rev Psychol. (2013) 64:257–83. doi: 10.1146/annurev-psych-113011-143802
23. Walther S, Alexaki D, Stegmayer K, Vanbellingen T, Bohlhalter S. Conceptual disorganization impairs hand gesture performance in schizophrenia. Schizophr Res. (2020) 215:467–8. doi: 10.1016/j.schres.2019.09.001
24. Matthews N, Gold BJ, Sekuler R, Park S. Gesture imitation in schizophrenia. Schizophr Bull. (2013) 39:94–101. doi: 10.1093/schbul/sbr062
25. Lavelle M, Dimic S, Wildgrube C, Mccabe R, Priebe S. Non-verbal communication in meetings of psychiatrists and patients with schizophrenia. Acta Psychiatr Scand. (2015) 131:197–205. doi: 10.1111/acps.12319
26. Pavlidou A, Chapellier V, Maderthaner L, Von Känel S, Walther S. Using dynamic point light display stimuli to assess gesture deficits in schizophrenia. Schizophr Res Cogn. (2022) 28:100240. doi: 10.1016/j.scog.2022.100240
27. Lavelle M, Healey PG, Mccabe R. Is nonverbal communication disrupted in interactions involving patients with schizophrenia? Schizophr Bull. (2013) 39:1150–8. doi: 10.1093/schbul/sbs091
28. Worswick E, Dimic S, Wildgrube C, Priebe S. Negative Symptoms and avoidance of social interaction: a study of non-verbal behaviour. Psychopathology. (2018) 51:1–9. doi: 10.1159/000484414
29. Berndl K, Von Cranach M, Grusser OJ. Impairment of perception and recognition of faces, mimic expression and gestures in schizophrenic patients. Eur Arch Psychiatry Neurol Sci. (1986) 235:282–91. doi: 10.1007/BF00515915
30. Bucci S, Startup M, Wynn P, Heathcote A, Baker A, Lewin TJ. Referential delusions of communication and reality discrimination deficits in psychosis. Br J Clin Psychol. (2008) 47:323–34. doi: 10.1348/014466508X280952
31. Nagels A, Kircher T, Grosvald M, Steines M, Straube B. Evidence for gesture-speech mismatch detection impairments in schizophrenia. Psychiatry Res. (2019) 273:15–21. doi: 10.1016/j.psychres.2018.12.107
32. Bohlhalter S, Hattori N, Wheaton L, Fridman E, Shamim EA, Garraux G, et al. Gesture subtype-dependent left lateralization of praxis planning: an event-related fMRI study. Cereb Cortex. (2009) 19:1256–62. doi: 10.1093/cercor/bhn168
33. Hermsdorfer J, Li Y, Randerath J, Roby-Brami A, Goldenberg G. Tool use kinematics across different modes of execution. Implications for action representation and apraxia. Cortex. (2013) 49:184–99. doi: 10.1016/j.cortex.2011.10.010
34. Thakkar KN, Peterman JS, Park S. Altered brain activation during action imitation and observation in schizophrenia: a translational approach to investigating social dysfunction in schizophrenia. Am J Psychiatry. (2014) 171:539–48. doi: 10.1176/appi.ajp.2013.13040498
35. Stegmayer K, Bohlhalter S, Vanbellingen T, Federspiel A, Moor J, Wiest R, et al. Structural brain correlates of defective gesture performance in schizophrenia. Cortex. (2016) 78:125–37. doi: 10.1016/j.cortex.2016.02.014
36. Viher PV, Stegmayer K, Giezendanner S, Federspiel A, Bohlhalter S, Vanbellingen T, et al. Cerebral white matter structure is associated with DSM-5 schizophrenia symptom dimensions. NeuroImage Clin. (2016) 12:93–9. doi: 10.1016/j.nicl.2016.06.013
37. Viher PV, Stegmayer K, Kubicki M, Karmacharya S, Lyall AE, Federspiel A, et al. The cortical signature of impaired gesturing: findings from schizophrenia. NeuroImage Clin. (2018) 17:213–21. doi: 10.1016/j.nicl.2017.10.017
38. Viher PV, Abdulkadir A, Savadijev P, Stegmayer K, Kubicki M, Makris N, et al. Structural organization of the praxis network predicts gesture production: evidence from healthy subjects and patients with schizophrenia. Cortex. (2020) 132:322–33. doi: 10.1016/j.cortex.2020.05.023
39. Stegmayer K, Bohlhalter S, Vanbellingen T, Federspiel A, Wiest R, Muri RM, et al. Limbic interference during social action planning in schizophrenia. Schizophr Bull. (2018) 44:359–68. doi: 10.1093/schbul/sbx059
40. Wuthrich F, Viher PV, Stegmayer K, Federspiel A, Bohlhalter S, Vanbellingen T, et al. Dysbalanced resting-state functional connectivity within the praxis network is linked to gesture deficits in schizophrenia. Schizophr Bull. (2020) 46:905–15. doi: 10.1093/schbul/sbaa008
41. Fogassi L, Luppino G. Motor functions of the parietal lobe. Curr Opin Neurobiol. (2005) 15:626–31. doi: 10.1016/j.conb.2005.10.015
42. Gottlieb J. From thought to action: the parietal cortex as a bridge between perception, action, and cognition. Neuron. (2007) 53:9–16. doi: 10.1016/j.neuron.2006.12.009
43. Goldenberg G. Apraxia and the parietal lobes. Neuropsychologia. (2009) 47:1449–59. doi: 10.1016/j.neuropsychologia.2008.07.014
44. Binkofski F, Buccino G. Motor functions of the broca’s region. Brain Lang. (2004) 89:362–9. doi: 10.1016/S0093-934X(03)00358-4
45. Chung CL, Mak MK, Hallett M. Transcranial magnetic stimulation promotes gait training in Parkinson disease. Ann Neurol. (2020) 88:933–45. doi: 10.1002/ana.25881
46. Lefebvre S, Pavlidou A, Walther S. What is the potential of neurostimulation in the treatment of motor symptoms in schizophrenia? Expert Rev Neurother. (2020) 20:697–706. doi: 10.1080/14737175.2020.1775586
47. Walther S, Alexaki D, Schoretsanits G, Weiss F, Vladimirova I, Stegmayer K, et al. Inhibitory repetitive transcranial magnetic stimulation to treat psychomotor slowing: a transdiagnostic, mechanism-based double-blind controlled trial. Schizophr Bull. (2020) 1:sgaa020. doi: 10.1093/schizbullopen/sgaa020
48. Walther S, Kunz M, Muller M, Zurcher C, Vladimirova I, Bachofner H, et al. Single session transcranial magnetic stimulation ameliorates hand gesture deficits in schizophrenia. Schizophr Bull. (2020) 46:286–93. doi: 10.1093/schbul/sbz078
49. Lefaucheur JP. Transcranial magnetic stimulation. Handb Clin Neurol. (2019) 160:559–80. doi: 10.1016/B978-0-444-64032-1.00037-0
50. Vanbellingen T, Pastore-Wapp M, Kubel S, Nyffeler T, Schupfer AC, Kiefer C, et al. Interhemispheric facilitation of gesturing: a combined theta burst stimulation and diffusion tensor imaging study. Brain Stimul. (2020) 13:457–63. doi: 10.1016/j.brs.2019.12.013
51. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull. (2006) 32:S44–63. doi: 10.1093/schbul/sbl029
52. Mancuso F, Horan WP, Kern RS, Green MF. Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophr Res. (2011) 125:143–51. doi: 10.1016/j.schres.2010.11.007
53. Schmidt SJ, Mueller DR, Roder V. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr Bull. (2011) 37:S41–54. doi: 10.1093/schbul/sbr079
54. Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res. (2004) 72:1–3. doi: 10.1016/j.schres.2004.09.006
55. Brown EC, Tas C, Brune M. Potential therapeutic avenues to tackle social cognition problems in schizophrenia. Expert Rev Neurother. (2012) 12:71–81. doi: 10.1586/ern.11.183
56. Mueller DR, Schmidt SJ, Roder V. One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients. Schizophr Bull. (2015) 41:604–16. doi: 10.1093/schbul/sbu223
57. Moritz S, Klein JP, Lysaker PH, Mehl S. Metacognitive and cognitive-behavioral interventions for psychosis: new developments. Dialogues Clin Neurosci. (2019) 21:309–17. doi: 10.31887/DCNS.2019.21.3/smoritz
58. Mueller DR, Roder V. Integrated psychological therapy for schizophrenia patients. Expert Rev Neurother. (2007) 7:1–3. doi: 10.1586/14737175.7.1.1
59. Roder V, Muller DR. INT – Integrierte Neurokognitive Therapie Bei Schizophren Erkrankten. Berlin: Springer (2013). doi: 10.1007/978-3-642-21440-0
60. Mueller DR, Khalesi Z, Benzing V, Castiglione CI, Roder V. Does integrated neurocognitive therapy (INT) reduce severe negative symptoms in schizophrenia outpatients? Schizophr Res. (2017) 188:92–7. doi: 10.1016/j.schres.2017.01.037
61. De Mare A, Cantarella M, Galeoto G. Effectiveness of integrated neurocognitive therapy on cognitive impairment and functional outcome for schizophrenia outpatients. Schizophr Res Treatment. (2018) 2018:2360697. doi: 10.1155/2018/2360697
62. Mueller DR, Khalesi Z, Roder V. Can cognitive remediation in groups prevent relapses? Results of a 1-year follow-up randomized controlled trial. J Nerv Ment Dis. (2020) 208:362–70. doi: 10.1097/NMD.0000000000001146
63. Wolwer W, Frommann N. Social-cognitive remediation in schizophrenia: generalization of effects of the training of affect recognition (TAR). Schizophr Bull. (2011) 37:S63–70. doi: 10.1093/schbul/sbr071
64. Wolwer W, Frommann N, Halfmann S, Piaszek A, Streit M, Gaebel W. Remediation of impairments in facial affect recognition in schizophrenia: efficacy and specificity of a new training program. Schizophr Res. (2005) 80:295–303. doi: 10.1016/j.schres.2005.07.018
65. Grant N, Lawrence M, Preti A, Wykes T, Cella M. Social cognition interventions for people with schizophrenia: a systematic review focussing on methodological quality and intervention modality. Clin Psychol Rev. (2017) 56:55–64. doi: 10.1016/j.cpr.2017.06.001
66. Dark F, Harris M, Gore-Jones V, Newman E, Whiteford H. Implementing cognitive remediation and social cognitive interaction training into standard psychosis care. BMC Health Serv Res. (2018) 18:458. doi: 10.1186/s12913-018-3240-5
67. Wykes T, Van Der Gaag M. Is it time to develop a new cognitive therapy for psychosis–cognitive remediation therapy (CRT)? Clin Psychol Rev. (2001) 21:1227–56. doi: 10.1016/S0272-7358(01)00104-0
68. Cavallaro R, Anselmetti S, Poletti S, Bechi M, Ermoli E, Cocchi F, et al. Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation. Psychiatry Res. (2009) 169:191–6. doi: 10.1016/j.psychres.2008.06.027
69. Mulller DR, Roder V, Brenner HD. Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a meta-analysis. Schizophr Res. (2004) 67:202–202.
70. Roder V, Muller DR, Brenner HD. Integrated psychological therapy (IPT) for schizophrenia patients in different settings, patient sub samples and site conditions: a meta-analysis. Eur Psychiatry. (2004) 19:76s–7s.
71. Kopelowicz A, Liberman RP, Zarate R. Recent advances in social skills training for schizophrenia. Schizophr Bull. (2006) 32 Suppl 1:S12–23. doi: 10.1093/schbul/sbl023
72. Mcgurk SR, Twamley EW, Sitzer DI, Mchugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. (2007) 164:1791–802. doi: 10.1176/appi.ajp.2007.07060906
73. Eack SM, Pogue-Geile MF, Greenwald DP, Hogarty SS, Keshavan MS. Mechanisms of functional improvement in a 2-year trial of cognitive enhancement therapy for early schizophrenia. Psychol Med. (2011) 41:1253–61. doi: 10.1017/S0033291710001765
74. Goldsworthy MR, Vallence AM, Yang R, Pitcher JB, Ridding MC. Combined transcranial alternating current stimulation and continuous theta burst stimulation: a novel approach for neuroplasticity induction. Eur J Neurosci. (2016) 43:572–9. doi: 10.1111/ejn.13142
75. Kolb AY, Kolb DA. Learning styles and learning spaces: enhancing experiential learning in higher education. Acad Manag Learn Edu. (2005) 4:193–212. doi: 10.5465/amle.2005.17268566
76. Beidas RS, Cross W, Dorsey S. Show me, don’t tell me: behavioral rehearsal as a training and analogue fidelity tool. Cogn Behav Pract. (2014) 21:1–11. doi: 10.1016/j.cbpra.2013.04.002
77. Vanbellingen T, Kersten B, Van Hemelrijk B, Van De Winckel A, Bertschi M, Muri R, et al. Comprehensive assessment of gesture production: a new test of upper limb apraxia (TULIA). Eur J Neurol. (2010) 17:59–66. doi: 10.1111/j.1468-1331.2009.02741.x
78. Rosenthal R, Hall JA, Di Matteo MR, Rogers PL, Archer D. Sensitivity toNonverbal Communication: The PONS Test. Baltimore, MD: John HopkinsUniversity Press.
79. Mozaz M, Roth LJG, Anderson JM, Crucian GP, Heilman KM. Postural knowledge of transitive pantomimes and intransitive gestures. J Int Neuropsychol Soc. (2002) 8:958–62. doi: 10.1017/S1355617702870114
80. Bohlhalter S, Vanbellingen T, Bertschi M, Wurtz P, Cazzoli D, Nyffeler T, et al. Interference with gesture production by theta burst stimulation over left inferior frontal cortex. Clin Neurophysiol. (2011) 122:1197–202. doi: 10.1016/j.clinph.2010.11.008
81. Andreasen NC, Flaum M, Arndt S. The comprehensive assessment of symptoms and history (Cash) – an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. (1992) 49:615–23. doi: 10.1001/archpsyc.1992.01820080023004
82. Kroliczak G, Frey SH. A common network in the left cerebral hemisphere represents planning of tool use pantomimes and familiar intransitive gestures at the hand-independent level. Cerebral Cortex. (2009) 19:2396–410. doi: 10.1093/cercor/bhn261
83. Johansson G. Visual perception of biological motion and a model for its analysis. Percept Psychophys. (1973) 14:201–11. doi: 10.3758/BF03212378
84. Pavlidou A, Schnitzler A, Lange J. Interactions between visual and motor areas during the recognition of plausible actions as revealed by magnetoencephalography. Hum Brain Mapp. (2014) 35:581–92. doi: 10.1002/hbm.22207
85. Pavlidou A, Schnitzler A, Lange J. Distinct spatio-temporal profiles of beta-oscillations within visual and sensorimotor areas during action recognition as revealed by MEG. Cortex. (2014) 54:106–16. doi: 10.1016/j.cortex.2014.02.007
86. Manera V, Schouten B, Becchio C, Bara BG, Verfaillie K. Inferring intentions from biological motion: a stimulus set of point-light communicative interactions. Behav Res Methods. (2010) 42:168–78. doi: 10.3758/BRM.42.1.168
87. Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull. (2005) 31:882–7. doi: 10.1093/schbul/sbi049
88. Robertson DA, Hargreaves A, Kelleher EB, Morris D, Gill M, Corvin A, et al. Social dysfunction in schizophrenia: an investigation of the GAF scale’s sensitivity to deficits in social cognition. Schizophr Res. (2013) 146:363–5. doi: 10.1016/j.schres.2013.01.016
89. Tandon R. Definition of psychotic disorders in the DSM-5 too radical, too conservative, or just right! Schizophr Res. (2013) 150:1–2. doi: 10.1016/j.schres.2013.08.002
90. Jaaskelainen E, Juola P, Hirvonen N, Mcgrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. (2013) 39:1296–306. doi: 10.1093/schbul/sbs130
91. Shivashankar S, Telfer S, Arunagiriraj J, Mckinnon M, Jauhar S, Krishnadas R, et al. Has the prevalence, clinical presentation and social functioning of schizophrenia changed over the last 25 years? Nithsdale schizophrenia survey revisited. Schizophr Res. (2013) 146:349–56. doi: 10.1016/j.schres.2013.02.006
92. Pavlidou A, Walther S. Using virtual reality as a tool in the rehabilitation of movement abnormalities in schizophrenia. Front Psychol. (2021) 11:607312. doi: 10.3389/fpsyg.2020.607312
93. Suffel A, Nagels A, Steines M, Kircher T, Straube B. Feeling addressed! The neural processing of social communicative cues in patients with major depression. Hum Brain Mapp. (2020) 41:3541–54. doi: 10.1002/hbm.25027
94. Pavlidou A, Viher PV, Bachofner H, Weiss F, Stegmayer K, Shankman SA, et al. Hand gesture performance is impaired in major depressive disorder: a matter of working memory performance? J Affect Disord. (2021) 292:81–8. doi: 10.1016/j.jad.2021.05.055
95. Nagels A, Kircher T, Steines M, Grosvald M, Straube B. A brief self-rating scale for the assessment of individual differences in gesture perception and production. Learn Individ Differ. (2015) 39:73–80. doi: 10.1016/j.lindif.2015.03.008
96. Dollfus S, Mach C, Morello R. Self-evaluation of negative symptoms: a novel tool to assess negative symptoms. Schizophr Bull. (2016) 42:571–8. doi: 10.1093/schbul/sbv161
97. Oei TPS, Shuttlewood GJ. Development of a satisfaction with therapy and therapist scale. Aust N Z J Psychiatry. (1999) 33:748–53. doi: 10.1080/j.1440-1614.1999.00628.x
98. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (Panss) for schizophrenia. Schizophr Bull. (1987) 13:261–76. doi: 10.1093/schbul/13.2.261
99. Kirkpatrick B, Strauss GP, Linh N, Fischer BA, Daniel DG, Cienfuegos A, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. (2011) 37:300–5. doi: 10.1093/schbul/sbq059
100. Kircher T, Krug A, Stratmann M, Ghazi S, Schales C, Frauenheim M, et al. A rating scale for the assessment of objective and subjective formal thought and language disorder (TALD). Schizophr Res. (2014) 160:216–21. doi: 10.1016/j.schres.2014.10.024
101. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB – a frontal assessment battery at bedside. Neurology. (2000) 55:1621–6. doi: 10.1212/WNL.55.11.1621
102. Strik W, Wopfner A, Horn H, Koschorke P, Razavi N, Walther S, et al. The bern psychopathology scale for the assessment of system-specific psychotic symptoms. Neuropsychobiology. (2010) 61:197–209. doi: 10.1159/000297737
103. Buchanan RW, Heinrichs DW. The neurological evaluation scale (Nes) – a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. (1989) 27:335–50. doi: 10.1016/0165-1781(89)90148-0
104. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia.1. Rating scale and standardized examination. Acta Psychiatr Scand. (1996) 93:129–36. doi: 10.1111/j.1600-0447.1996.tb09814.x
105. Dantchev N, Widlocher DJ. The measurement of retardation in depression. J Clin Psychiatry. (1998) 59:19–25.
106. Fahn S, Elton R. Members of the UPDRS development committee the unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M editors. Recent Developments in Parkinson’s Disease. (Florham Park, NJ: McMellam Health Care Information) (1987). p. 153–63.
107. Guy W. ”ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville: MD: National Institute of Mental Health (1976). p. 76–338.
108. Gebhardt S, Hartling F, Hanke M, Mittendorf M, Theisen FM, Wolf-Ostermann K, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry. (2006) 15:371–82. doi: 10.1007/s00787-006-0544-5
109. Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. (2008) 34:1211–20. doi: 10.1093/schbul/sbm145
110. Blackburn HL, Benton AL. Revised administration and scoring of the digit span test. J Consult Psychol. (1957) 21:139–43. doi: 10.1037/h0047235
111. Brown L, Sherbenou RJ, Johnsen SK. Test of Nonverbal Intelligence (TONI). 3rd ed. Austin, TX: Pro-Ed Inc (1997).
112. Thaler NS, Strauss GP, Sutton GP, Vertinski M, Ringdahl EN, Snyder JS, et al. Emotion perception abnormalities across sensory modalities in bipolar disorder with psychotic features and schizophrenia. Schizophr Res. (2013) 147:287–92. doi: 10.1016/j.schres.2013.04.001
113. Nummenmaa L, Glerean E, Hari R, Hietanen JK. Bodily maps of emotions. Proc Natl Acad Sci USA. (2014) 111:646–51. doi: 10.1073/pnas.1321664111
114. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. (2000) 101:323–9. doi: 10.1111/j.1600-0447.2000.tb10933.x
115. Mausbach BT, Depp CA, Bowie CR, Harvey PD, Mcgrath JA, Thronquist MH, et al. Sensitivity and specificity of the UCSD performance-based skills assessment (UPSA-B) for identifying functional milestones in schizophrenia. Schizophr Res. (2011) 132:165–70. doi: 10.1016/j.schres.2011.07.022
Keywords: communication, social cognition, psychosis, theta burst stimulation, transcranial magnetic stimulation, intervention, cognitive remediation, schizophrenia
Citation: Chapellier V, Pavlidou A, Mueller DR and Walther S (2022) Brain Stimulation and Group Therapy to Improve Gesture and Social Skills in Schizophrenia—The Study Protocol of a Randomized, Sham-Controlled, Three-Arm, Double-Blind Trial. Front. Psychiatry 13:909703. doi: 10.3389/fpsyt.2022.909703
Received: 27 April 2022; Accepted: 13 June 2022;
Published: 07 July 2022.
Edited by:
Luca De Peri, Cantonal Sociopsychiatric Organization, SwitzerlandReviewed by:
Stefano Barlati, University of Brescia, ItalyDaria Smirnova, Samara State Medical University, Russia
Copyright © 2022 Chapellier, Pavlidou, Mueller and Walther. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Victoria Chapellier, dmljdG9yaWEuY2hhcGVsbGllckB1cGQudW5pYmUuY2g=